A.I.
AI in Clinical trials - Key insights from industry experts
When OpenAI unveiled ChatGPT in November 2022, it ignited unprecedented interest in artificial intelligence. Three years later, generative AI and machine learning have caused seismic shifts in industries worldwide. The pharmaceutical industry is not left out of this shift, with Roots Analysis reporting that they expect AI within clinical trials to grow at a compound annual growth rate of 16% through 2035. This growth is driven by belief in AI’s unique ability to process and analyze massive datasets at groundbreaking speeds, identifying patterns and generating insights that would be impossible to discover through traditional methods. By leveraging these capabilities, pharmaceutical companies hope to fundamentally reimagine core aspects of clinical trials, from initial design through final data analysis.
DPHARM ‘24: Top news and trends from this year’s conference
With the 14th annual DPHARM® wrapping up, we talked to our peers across the industry to find out what the big themes and takeaways were from this year’s conference.
What happened at ASCO 2024
The annual American Society of Clinical Oncology (ASCO) meeting in Chicago highlighted the latest new molecules, methods of care, and innovation in cancer care.
As the show closed out, we checked in with our associates to see what they thought were the biggest news and trends of the show.
.png)
DIA 2023 Recap: Discover DIA’s biggest news and top trends
Over the last four days, the DIA 2023 conference has Illuminated downtown Boston as thousands of “industry, regulatory, government, academics, and patients” come together to “problem-solve, and discuss global and local challenges facing the life sciences community.”
Much like JP Morgan week and SCOPE before it, what happens at DIA often makes waves across our industry, helping set the tone for our future.
Thus, we’re providing some of the biggest and brightest takeaways from this week’s conference below.